Drug Index

Rilpivirine

 
print

Mechanism :

As a NNRTI, rilpivirine has activity against HIV-1 by binding to reverse transcriptase.


Indication :

• Treatment of HIV-1 infections in antiretroviral treatment-naive patients =12 years of age and weighing =35 kg


Contraindications :

Co-administration with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin), antimycobacterial (rifampin, rifapentine), proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole), systemic dexamethasone (more than a single dose).


Dosing :

≥12 years and ≥35 kg: 25 mg PO once daily.


Adverse Effect :

Depression, headache, drowsiness, hypocortisolism, increased serum cholesterol & triglycerides, nausea, increased AST and ALT, insomnia, skin rash, abdominal pain, increased serum bilirubin and creatinine.


Interaction :

Antacids: May decrease the serum concentration of Rilpivirine.
Antihepaciviral Combination Products: May increase the serum concentration of Rilpivirine.
CYP3A4 Inducers: May increase the metabolism of CYP3A4 Substrates.
CYP3A4 Inhibitors: May increase the serum concentration of Rilpivirine.
Dexamethasone: May decrease the serum concentration of Rilpivirine.
Didanosine: Rilpivirine may decrease the absorption of Didanosine.
Macrolide Antibiotics: May increase the serum concentration of Rilpivirine.
Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the serum concentration of Rilpivirine.
Rifabutin, Rifamycin: May decrease the serum concentration of Rilpivirine.


07/18/2019 09:49:47 Rilpivirine
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0